Here's the short version. Sermorelin nudges your pituitary to release more growth hormone, and that part shows up fast in studies. What changes after that, and when, is much less clear. The adult evidence is thin. The cited adult studies enrolled 10 to 19 people, with hormone measurements after 14 days to 16 weeks [5] [7] [8].
A separate 12-week trial of Geref in 31 men with HIV-associated lipodystrophy found secondary DXA body-composition changes. That disease-specific checkpoint does not establish a response timetable for healthy adults [1].
What the studies measured, and when
In the studies below, hormone changes were measured as early as 14 days, while childhood growth was assessed at 6 and 12 months. It depends on who took it. It also depends on what was measured. Adult hormone findings do not establish a reliable timeline for feeling better.
| Study | Who | Design and size | Time point | What changed | Strength of evidence |
|---|---|---|---|---|---|
| Thorner 1996 [6] | Children with growth hormone deficiency | Open-label, no control group; 110 treated, 86 analyzed | 6 and 12 months | Growth rate rose from 1.6 to 3.1 inches (4.1 to 8.0 cm) a year at 6 months and was 2.8 inches (7.2 cm) at 12 months; 74% responded well at 6 months | Moderate: large for this field, but no comparison group |
| Vittone 1997 [7] | 11 healthy men aged 64 to 76 with low IGF-1 | Before-and-after, no control group | 6 weeks | Night-time growth hormone up; no change in IGF-1, weight, or DXA measures of lean and fat tissue; 2 of 6 strength tests improved | Low: tiny and uncontrolled |
| Khorram 1997 [8] | 19 healthy adults over 60 (9 men, 10 women) | Single-blind; 4 weeks of placebo, then 16 weeks on the analog | 4 to 16 weeks | Growth hormone output up 107% in men and 70% in women; IGF-1 up 28%. A different molecule, not sermorelin | Low: small, and not the same drug |
Sermorelin is GHRH(1-29). The Khorram study used [Nle27]GHRH(1-29), a close relative with one amino acid swapped.
The six-week adult study measured a hormone change without a body-composition change; the 14-day study measured hormone restoration, not clinical benefit. If you are weighing sermorelin for body composition, see our guide to whether sermorelin builds muscle.
Clinic timelines (2 to 4 weeks for sleep, months for body changes) aren't trial results
The studies summarized here do not validate a commercial week-by-week sleep or energy timetable. Older sleep-laboratory studies of GHRH measured overnight sleep, with differing protocols and results; they do not establish a personal week-by-week response to a commercially compounded sermorelin regimen [3] [4].
That doesn't mean people feel nothing. Some do. It means a timeline like "better sleep by week three" is a clinic's experience, not a measured result. Treat it as a rough expectation to discuss with your prescriber, not a promise.
There's also a measurement problem. Sleep and energy are hard to rate yourself, and they shift with stress, season and routine. Without a comparison group, nobody can say how much of a change came from the drug. These results cannot predict when an individual will notice a benefit.
Growth hormone moves first; IGF-1 is what prescribers test
A rise in growth hormone is the first thing sermorelin changes. But IGF-1 is the number prescribers usually check, because it carries most of growth hormone's effects on tissue. In the older men, IGF-1 didn't move at six weeks [7].
The researchers themselves suggested why. They wrote that the regimen they tested had weaker effects on growth hormone and IGF-1 than they had hoped. That's a comment on one study's design, and your prescriber sets your own plan.
The analog study tells a slightly different story. With its related molecule, IGF-1 rose 28% within four weeks and stayed up for 12 weeks, while growth hormone output stayed higher through 16 weeks [8]. It was a study of immune markers in 19 people, and the drug isn't sermorelin. So it's a hint about the timeline, not proof.
Children with growth hormone deficiency showed the clearest timeline
In the use sermorelin was once approved for, children's growth rate roughly doubled within six months. It's the clearest timeline in any sermorelin study. In 86 children with growth hormone deficiency, average growth went from 1.6 inches (4.1 cm) a year to 3.1 inches (8.0 cm) at six months and 2.8 inches (7.2 cm) at a year [6].
The same study reported no change in fasting glucose and no excess rise in IGF-1. It's a strong signal for that group. It says little about a healthy adult using sermorelin for energy or aging, because the bodies and the goals are different.
Baseline hormone levels and age differ, so prescribers check labs
Prescribers usually check IGF-1 before you start and again at follow-up to judge whether sermorelin is doing anything. Baseline hormone levels, age and health differ a lot from person to person. A lab number gives you both something firmer than "I think I sleep better".
Expect the first real check-in to be a lab result, not a feeling. That's normal. It's also why a program that never mentions follow-up labs leaves you guessing. If you want a quick way to sort programs by what you care about, the 30-second match asks about labs and budget up front.
- Ask which labs the program orders before the first shipment, and which ones it repeats.
- Ask when the first follow-up is, and what result would mean it's working.
- Ask what happens if nothing changes by then.
Programs differ here. Some require baseline blood work, some offer it as an extra, and some leave it to the clinician. The steps are laid out in how to get sermorelin prescribed, and what each plan charges is in our sermorelin cost guide.
If nothing has changed, follow-up labs are how you'll know
If nothing has changed after the period your prescriber set, the follow-up labs tell you whether it's doing anything at the hormone level. That's the honest checkpoint. A lack of felt change on its own is consistent with the adult evidence, where IGF-1 didn't move at six weeks [7].
Your prescriber decides whether to change the plan, keep going or stop. If sleep is the main reason you're looking, the sleep and recovery shortlist covers other options too. For a broader hormone picture, start with the hormones shortlist.
Sermorelin isn't currently FDA-approved; it's dispensed as a compounded drug
Sermorelin isn't currently FDA-approved. The maker discontinued Geref, the brand, in 2008, and FDA withdrew the approvals in 2009 [10]. In 2013, FDA said Geref wasn't withdrawn for safety or effectiveness reasons [9].
Today it reaches patients as a compounded prescription, made by a pharmacy for a named patient. For outsourcing facilities, FDA lists sermorelin acetate as under evaluation (503B Category 1, list revised March 2025) [11]. Compounded drugs aren't FDA-approved, and FDA doesn't check them for safety or quality before they're dispensed.